{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:00:40Z","timestamp":1775782840030,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T00:00:00Z","timestamp":1450656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T00:00:00Z","timestamp":1450656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s12029-015-9790-4","type":"journal-article","created":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T08:43:33Z","timestamp":1450687413000},"page":"75-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal"],"prefix":"10.1007","volume":"47","author":[{"given":"Suilane Coelho Ribeiro","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila Motta Venchiarutti","family":"Moniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Riechelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra Kichfy","family":"Alex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Ignez","family":"Braghirolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Bariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caio","family":"Nahas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Marcelo Gehm","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,21]]},"reference":[{"key":"9790_CR1","unstructured":"National Cancer Institute at the National Institutes of Health [Internet] [Place unknown][date unknown]. Available from: http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/anal\/HealthProfessional\/page2"},{"key":"9790_CR2","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1002\/ijc.23028","volume":"121","author":"H Patel","year":"2007","unstructured":"Patel H, Polanco-Echeverry G, Segditas S, et al. Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous carcinoma. Int J Cancer. 2007;121:2668\u201373.","journal-title":"Int J Cancer"},{"key":"9790_CR3","first-page":"1","volume":"00","author":"R Glynne-Jones","year":"2014","unstructured":"Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann of Oncol. 2014;00:1\u201311.","journal-title":"Ann of Oncol"},{"key":"9790_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","volume":"348","author":"UKCCR Anal Cancer Working party","year":"1996","unstructured":"UKCCR Anal Cancer Working party. Epidermoid anal cancer: results from the UKCCR randomized trial of radiotherapy alone versus radiotherapy, 5- fluorouracil and mitomycin. Lancet. 1996;348:1049\u201354.","journal-title":"Lancet"},{"key":"9790_CR5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040\u20139.","journal-title":"J Clin Oncol"},{"key":"9790_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0959-8049(02)00377-5","volume":"39","author":"JF Bosset","year":"2003","unstructured":"Bosset JF, Roelofsen F, Morgan DAL, et al. Shortened irradiation schedule, continous infusion of 5-fluorouracil and fractionation of mitomycin in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer. 2003;39:45\u201351.","journal-title":"Eur J Cancer"},{"issue":"16","key":"9790_CR7","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1002\/cncr.25943","volume":"117","author":"JH Park","year":"2011","unstructured":"Park JH, Yoon SH, Yu CS, Kim JH, Kim TW, Kim JC. Ramdomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Cancer. 2011;117(16):3703.","journal-title":"Cancer"},{"key":"9790_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","volume":"13","author":"RD Hofheinz","year":"2012","unstructured":"Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13:579\u201388.","journal-title":"Lancet Oncol."},{"key":"9790_CR9","doi-asserted-by":"publisher","unstructured":"Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015. Nov;107(11). doi:10.1093\/jnci\/djv248.","DOI":"10.1093\/jnci\/djv248"},{"issue":"1","key":"9790_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","volume":"72","author":"R Glynne- Jones","year":"2008","unstructured":"Glynne- Jones R, Meadows H, Wan s, et al. National cancer research institute anal subgroup and colorectal clinical oncology group. EXTRA\u2014a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin in anal cancer. Int J Radiation Oncol Biol Phys. 2008;72(1):119\u201326.","journal-title":"Int J Radiation Oncol Biol Phys"},{"issue":"5","key":"9790_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ijrobp.2012.12.008","volume":"85","author":"MJ Deenen","year":"2013","unstructured":"Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JHM, Cats A. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. Int J Radiation Oncol Biol Phys. 2013;85(5):201\u20137.","journal-title":"Int J Radiation Oncol Biol Phys"},{"key":"9790_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1748-717X-9-124","volume":"9","author":"G Thind","year":"2014","unstructured":"Thind G, Johal B, Follwell M, Kennecke HF. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. Radiat Oncol. 2014;9:124.","journal-title":"Radiat Oncol."},{"issue":"99","key":"9790_CR13","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/bjc.2014.467","volume":"111","author":"D Meulendjiks","year":"2014","unstructured":"Meulendjiks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens JH, et al. Chemoradiation with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J cancer. 2014;111(99):1726\u201333.","journal-title":"Br J cancer"},{"issue":"No 35 (December","key":"9790_CR14","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1200\/JCO.2012.44.8878","volume":"Vol 30","author":"JY Chin","year":"2012","unstructured":"Chin JY, Hong TS, Ryan DP. Mitomycin in anal cancer: still the standard of care. J Clin Oncol. 2012;Vol 30(No 35 (December 10)):4297\u2013301.","journal-title":"J Clin Oncol"},{"key":"9790_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/BF02586980","volume":"17","author":"N Nigro","year":"1974","unstructured":"Nigro N, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17:354\u201369.","journal-title":"Dis. Colon Rectum"},{"key":"9790_CR16","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","volume":"199","author":"JA Ajani","year":"2008","unstructured":"Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;199:1914\u201321.","journal-title":"JAMA"},{"key":"9790_CR17","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","volume":"14","author":"M Flam","year":"1996","unstructured":"Flam M, john M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527\u201339.","journal-title":"J Clin Oncol"},{"issue":"3","key":"9790_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0360-3016(97)00329-5","volume":"39","author":"EC Constantinou","year":"1997","unstructured":"Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, Delane TF. Time -dose consideration in the treatment of anal cancer. Int J Radiat Oncol Biol Phys. 1997;39(3):657.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"9790_CR19","first-page":"205","volume":"2","author":"M John","year":"1996","unstructured":"John M, Pajok T, Flam M, Hoffman J, Markoe A, Wolkov H, et al. Dose escalation in chemoradiation for anal cancer:preliminary results of RTOG 92\u201308. Cancer J Sci Am. 1996;2(4):205.","journal-title":"Cancer J Sci Am"},{"issue":"4","key":"9790_CR20","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/0360-3016(96)00146-0","volume":"35","author":"JA Martenson","year":"1996","unstructured":"Martenson JA, Lipsitz SR, Wagner Jr H, Kaplan E, Otteman LA, Schuchter LM, et al. Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study. Int J Radiat Oncol Biol Phys. 1996;35(4):745.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9790_CR21","doi-asserted-by":"publisher","unstructured":"Glynne-Jones R, Adams RA, Jidal M, Meadows H. Endpoints in anal cancer: hopes for a common language. J Clin Oncol 2014;32(12):1281\u20132.doi:10.1200\/JCO.2014.55.1515.","DOI":"10.1200\/JCO.2014.55.1515"},{"key":"9790_CR22","doi-asserted-by":"crossref","unstructured":"Glynne-Jones R, James R, Meadows H, Begum R, et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP\/5FU in squamous cell carcinoma of the anus: Results of ACT II. J Clin Oncol 30, 2012;30(15) suppl (May 20 Supplement 4004).","DOI":"10.1200\/jco.2012.30.15_suppl.4004"},{"key":"9790_CR23","unstructured":"Common terminology criteria for adverse events Version 4.0.[Internet][Place unknown][cited 2010 June 2014]. Available from: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06 -14"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-015-9790-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-015-9790-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-015-9790-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-015-9790-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T11:14:13Z","timestamp":1628594053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-015-9790-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,21]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["9790"],"URL":"https:\/\/doi.org\/10.1007\/s12029-015-9790-4","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,21]]},"assertion":[{"value":"21 December 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with local ethical and regulatory requirements. It followed the recommendations to conduct clinical trials of the International Conference on Harmonization Good Clinical Practices. Informed consent was applied to all patients before inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}